Average Co-Inventor Count = 3.20
ph-index = 6
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Intercept Pharmaceuticals, Inc. (8 from 62 patents)
2. Antibe Therapeutics Inc. (5 from 10 patents)
3. Bar Pharmaceuticals S.r.l. (2 from 2 patents)
4. Bar Pharmaceuticals Societa' a Responsabilita' Limitata (1 from 1 patent)
5. Antibe Holdings Inc. (0 patent)
16 patents:
1. 11332450 - Isoxazole as FXR receptor agonists
2. 11117926 - Cholane derivatives for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases
3. 10987362 - Treatment of fibrosis using FXR ligands
4. 10407462 - Cholane derivatives for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases
5. 10258633 - Treatment of fibrosis using FXR ligands
6. 9763964 - Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
7. 9498484 - Treatment of fibrosis using FXR ligands
8. 9090652 - Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
9. 8546365 - Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
10. 8114857 - Derivatives of 4- or 5-aminosalicylic acid
11. 8114858 - Derivatives of 4- or 5-aminosalicylic acid
12. 7932244 - Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
13. 7910568 - Derivatives of 4- or 5-aminosalicylic acid
14. 7879827 - Derivatives of 4- or 5-aminosalicylic acid
15. 7858608 - Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions